Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network.

Front Oncol · 2023 · PMC10166989 · PMID 37182182

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

showed a trendp = 0.06so close (0.05 < p ≤ 0.1)

Patients with high-risk cytogenetic abnormalities showed a trend to lower PFS (median 24 vs. 39 months, p = 0.06; Figure 3E ) compared to those with standard risk.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.